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Abstract
BACKGROUND: Neonatal abstinence syndrome (NAS) is one of the consequences at birth 
affecting the newborn after discontinuation of prenatal drug exposure to mainly opioids. The 
objective of this study was to determine the extent of the problem in the state of West Virginia 
(WV) using a real-time statewide surveillance system.
METHODS: Project WATCH is a surveillance tool that since 1998 collects data on all infants 
born in the state of WV. NAS surveillance item was added to the tool in October 2016. This study 
examined all births (N = 23,667) in WV from October to December 2017. The data from six WV 
birthing facilities were audited for 1 month to evaluate how well this tool was capturing NAS data 
using κ-statistics.
RESULTS: The 2017 annual incidence rate of NAS was 51.3 per 1000 live births per year for all 
births and 50.6 per 1000 live births per year for WV residents only. The κ-coefficient between the 
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hospital medical records and Project WATCH data was 0.74 (95% confidence interval: 0.66–0.82) 
for NAS.
CONCLUSION: The study provides justification to develop effective systems of care for the 
mother–infant dyad affected by substance use, especially targeting pregnant women in rural 
communities.
INTRODUCTION
Neonatal abstinence syndrome (NAS) is a multi-system withdrawal syndrome of the 
newborn that presents shortly after birth when in utero exposure to illegal or prescription 
drugs (classically opioids) is suddenly discontinued at delivery.1,2 Some of the clinical signs 
that may appear within the first few days after birth and may include excessive sweating, 
tremors, high-pitched cry, poor feeding, watery stools, and excessive weight loss.3,4 
Negative long-term outcomes are also evident as these children have an increased risk of 
social and behavior abnormalities in early years,5 as well as poorer school performances 
than their peers.6
In the United States (US), the incidence rate of NAS in number of cases per 1000 live births 
per year has increased from 1.2 in 2000 to 3.4 in 20097 to 5.8 in 2012.8 In 2012, the 
estimated cost of admissions for infants diagnosed with NAS was nearly US$316 million 
nationally.9 The aggregate hospital charges for NAS totaled US$1.5 billion.8 Moreover, 
nearly 80% of the infants diagnosed with NAS are born to families whose health insurance 
coverage is through state-funded Medicaid programs,7,9 thus escalating the burden on the 
already strained healthcare system.10
The incidence of NAS is disproportionately higher in rural counties compared to urban 
counties and increasing much more rapidly in rural areas compared to urban areas.11 There 
are geographical disparities in NAS rates based on Appalachian mountain regional status as 
well; in the states of Kentucky and Tennessee, the rates of NAS were more in the 
Appalachian regions compared to the non-Appalachian regions.12,13
With the rise in the opioid epidemic nationally, the state of West Virginia (WV) has 
experienced a much higher rate of substance use due to the constellation of several socio-
demographic factors that negatively impact health behaviors. WV is the only state that is 
entirely within the Appalachian mountain region and nearly half of the people in the state 
live in rural areas.14,15 WV also has the highest age-adjusted drug overdose death rate in the 
nation.16 A study in 2009 showed that 19% of mothers used drugs or drank alcohol during 
pregnancy in WV.17 Stabler et al.18 examined the 2007–2013 WV Health Care Authority 
and Uniform Billing Data for WV and found that between 2007 to 2013 the incidence of 
NAS increased from 7.74 per 1000 live birth per year to 31.56 per 1000 live birth per year.18
Most studies use administrative data based on billing and coding from medical 
documentation to obtain NAS estimates, which leads to a few years of lag in presenting 
current NAS estimates.18–21 With the steep increase of substance use in the state of WV, this 
lag may lead to misrepresentation of the current crisis. The objective of the manuscript was 
to present the most current rate of NAS for WV as well as evaluate how well Project 
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WATCH surveillance tool was capturing NAS data in real time for the state. Given the rise in 
opioid epidemic and the parallel surge in infants with NAS nationally as well as in the state 
of WV, the results of this study have the potential to contribute to addressing this critical 
public health problem in one of the hardest hit states in the country by informing policy 
makers as to the true extent of the problem in real time.
METHODS
The study used data from Project WATCH (Working in Appalachia to identify at-risk 
infants, Critical congenital heart disease, and Hearing loss). This project as a statewide 
mandate since 1998 (House Bill 238822) focuses on collecting surveillance data on every 
infant born in WV birthing hospitals/facilities. More information about this project can be 
found elsewhere.23 In October 2016, Project WATCH collaborated with The West Virginia 
Perinatal Partnership and the WV Department of Health and Human Resources to expand its 
surveillance tool to include real-time information on substance use during pregnancy and 
presence of NAS at the time of infant discharge from the hospital. Given that Project 
WATCH has been used by all WV birthing hospitals for more than 20 years, the addition of 
a new surveillance item to this tool that captures real-time data appeared to be an ideal way 
to identify infants with NAS and accurately estimate the extent of the problem in WV.
The nurses at each WV birth facility completed the questionnaire form for Project WATCH 
before hospital discharge. Intrauterine substance exposure (IUSE) was assessed using 
several possible sources (self-report, documented in medical record, or/and positive drug 
screening test). In September 2014, WV neonatologists, pediatricians, hospital coders, and 
members of the West Virginia Perinatal Partnership met to develop a standardized definition 
for NAS as well as guidance for documenting exposure and withdrawal in newborns. The 
definition that was agreed upon was as follows: NAS is diagnosed when a baby has 
intrauterine exposure to a neuro-active substance, and exhibited clinical signs of withdrawal, 
regardless of whether or not pharmacological treatment is required. Training sessions on the 
standardized definition for NAS were conducted statewide at all birth facilities in 2015–
2016. Following the statewide training efforts, the IUSE and NAS surveillance items were 
added to the Project WATCH surveillance tool on 1 October 2016. Infants who had IUSE 
were assessed for signs of NAS consistent with the agreed upon statewide definition
This study examined all births in WV over a 15-month time period (1 October 2016 to 31 
December 2017). Nearly 16% of infants were born to mothers who live in the surrounding 
states of Kentucky, Maryland, Ohio, Pennsylvania, and Virginia, but gave birth in WV. The 
data were analyzed for all births as well as births for WV residents only. Within WV, the 55 
counties were clustered into six regions. These regions are based on the sub-state regions 
defined by the 2012–2014 National Survey on Drug Use and Health (NSDUH) conducted by 
the Substance Abuse and Mental Health Services Administration (SAMHSA). These regions 
were created to understand the geographic variability of substance use within WV, which in 
turn provided vital information for policy efforts.24 Most substance use data are analyzed 
using these regions, rather than using county-level data since not all counties have the same 
level of resources and people cross county lines to access services. Regions were compared 
on both the prevalence of IUSE and the incidence of NAS.25,26
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One-month data collection audit
Since Project WATCH started collecting data on substance use and NAS in October 2016, 
the research team wanted to assess the quality of data being recorded in Project WATCH 
database. Subsequently, a chart audit was performed on all births from six large birthing 
hospitals in WV for the month of January 2017. Detailed and standardized review 
instructions were provided to all hospital personnel who were to be responsible for data 
abstraction. Data abstraction was not blinded but data were deidentified before analysis. All 
births were reviewed to examine what was reported in the medical chart, which ICD-10 code 
was entered and what was reported by Project WATCH. The ICD-10-CM codes included 
P04.1–P04.4, P04.8, P04.9, and P96.1.27 The κ-coefficient was calculated to examine the 
level of agreement between the hospital medical records and the data from Project WATCH.
RESULTS
The results showed that in the select project period there were 23,667 births in the state of 
WV. The rate of IUSE and NAS for all births and for WV residents only (84%) is shown in 
Fig. 1. For the WV residents only, the incidence of NAS was 52.6 per 1000 live births per 
year (Fig. 1). The breakdown of the data by year 2016 (3 months) and 2017 (12 months) as 
well as the total for the 15-month period is shown in Table 1.
The results of IUSE and NAS rates according to the six predefined SAMHSA regions are 
displayed in Table 2 and Fig. 2. Region 1 had one of the highest prevalence of IUSE and the 
highest incidence of NAS in the state. Similar patterns were not found in other regions. For 
example, in region 4 the prevalence of the IUSE was the lowest, but the incidence of the 
NAS was the second highest in the state (Table 2).
The information on IUSE was gathered from multiple sources and could include more than 
one source per person. Of those with IUSE (n = 3350), nearly two-thirds (65.76%; 
confidence interval (CI): 64.15–67.37) had a positive drug screen during their labor and 
delivery hospital admission and nearly half of the women self-reported (52.72%; CI: 51.03–
54.14) or had a positive substance use information in their past medical records (50.90%; CI: 
49.20–52.59).
One-month data collection audit
There were 789 births in the six hospitals where the chart audits were performed. This 
represented 52% of 1521 births in Project WATCH database for all birth in January 2017 in 
WV. Out of 133 IUSE cases identified in the hospital medical records, 107 (81%) were 
identified as IUSE cases by the Project WATCH surveillance data tool (κ-coefficient = 0.85 
(CI: 0.83–0.91)). For the NAS data, out of 79 cases identified in the hospital medical 
records, 56 (71%) were identified as NAS cases by the Project WATCH surveillance tool (κ-
coefficient = 0.74 (CI: 0.66–0.82). (Table 3). The ICD-10-CM code for NAS was recorded 
by less than half (47.25%) of the infants diagnosed with NAS in the combined data for the 
six hospitals.
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The study used a real-time surveillance system to assess the extent of NAS in a state that has 
been significantly impacted by the current opioid crisis. The rate of NAS was 53 cases per 
1000 live births per year, which was much higher than rate of NAS reported in earlier studies 
in 2013, that is, nearly 30 per 1000 live births per year.18,19 This rise was expected, as 
national trends show a significant increase in NAS diagnoses as well. However, based on the 
discordance between coding data and Project WATCH data, there is a level of concern that 
the earlier rates may have been grossly underestimated. WV is a rural Appalachian state and 
the results from this study showed that NAS rate was seven times higher in WV than what 
was found in rural regions of the country in 2013 (i.e., nearly 7 per 1000 live births per 
year).11 Moreover, this study demonstrated that the rate of NAS in WV is one of the highest 
in the country and nearly 10-fold the national estimate of5.8 per 1000 births live births per 
year in 2012.8
The rate of IUSE in WV was 14%, which is consistent with a study conducted in 2009.17 
Stitely et al.17 examined umbilical cord tissues of women who gave birth in 1 month in eight 
birth hospitals in WV and found 14% of mothers were positive for drug use. Based on the 
rising opioid epidemic in the state, we hypothesized that in 2017 the prevalence would be 
much higher than what was observed in 2009. One of the likely reasons for the 
underestimated prevalence in our study is the fact that data on IUSE was gathered through 
self-report, previous documentation, or drug testing at certain hospitals compared to the 
earlier study that used universal umbilical cord tissue samples.17 WV does not have a 
mandated maternal drug-screening program.
Geographical disparities in the rates of IUSE and NAS were also observed. The northern 
panhandle (region 1) has one of the highest rates of IUSE as well as NAS incidence. The 
northern central region 4 has the lowest prevalence of IUSE, but the second highest NAS 
rates. We postulate that the inconsistency in this particular region likely arises from a 
combination in obtaining accurate drug history data from mother as well as the possibility 
that physicians in region 4 may be more conservative in diagnosing NAS. Interestingly, our 
regional results are not consistent with the results from Stabler et al.,18 as they found the 
southern region 4 and region 5 had the highest rates of NAS in 2013.18 Some of the reasons 
for this discrepancy may be, (1) the use of administrative data source (ICD-9-CM codes) 
compared to the current study that uses the diagnosis made at the hospital and recorded by 
the nurses before hospital discharge, and (2) the likely steep increase of incidence between 
2013 and 2017. Furthermore, in 2017 the high-intensity drug trafficking areas (HIDTAs) in 
WV include regions 1, 5, and 6, which may explain the high prevalence of IUSE and NAS in 
region 1, but nonetheless fails to explain the lower incidence in regions 5 and 6 in the current 
study.28
The results of the audit found that Project WATCH was capturing the prevalence of IUSE 
and incidence of NAS reasonably well. However, the agreement between the hospital chart 
review and the Project WATCH data for IUSE was higher than the agreement between the 
Project WATCH data and NAS. One likely explanation for this observation is that one of the 
six hospitals, which incidentally had one of the highest contributions of birth data to the 
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audit, ultimately contributed a higher rate of NAS, which may be reflective of biases from 
the chart reviewers. Project WATCH had already used this audit data for quality 
improvement of its data collection process by training nurses on data entry and report. The 
audit data also revealed that only half of the infants diagnosed with NAS were identified 
utilizing the ICD-10-CM codes. Other studies have also shown that administrative data 
diagnostic codes under-represent the actual number of NAS cases diagnosed in the hospital.
20
Based on our results, Project WATCH appears to capture IUSE and NAS diagnoses via a 
novel, accurate, and cost-effective electronic surveillance tool. Although these data does not 
include births delivered outside the hospital (~0.01%), Project WATCH collects data on 
every infant born in WV birthing hospitals/facilities. This new data source shows improved 
ability to capture NAS cases compared to the traditional method of utilizing electronic 
claims data via ICD codes. Additionally, Project WATCH data are captured in real time 
allowing for timely surveillance of a leading public health issue in the state of WV. WV is 
one of a few states that collects surveillance data on NAS; four additional states (Florida, 
Georgia, Kentucky, and Tennessee) have legally mandated NAS as a reportable condition 
and have a passive surveillance system in place.29 States without a specific surveil-lance 
system for NAS report the condition via traditional methods such as diagnostic codes and 
hospital billing records (e.g., the State Hospital Discharge Database or State All Payer 
Claims data). Traditional methods used to survey the burden of NAS may have several 
months of lag from data collection to analysis.18–21 A real-time estimation of NAS has the 
potential to guide targeted resources and interventions in a timely manner.
Some of the limitations include the fact that Project WATCH does not gather information on 
the type(s) of specific substances that the infant is exposed to in utero. It is likely that many 
of the infants in this study were exposed to multiple substances simultaneously. Although 
the effect of polysubstance use on the occurrence of NAS is controversial,30 results from a 
large population-based cohort study showed significant increases in the risk of NAS 
associated with opioid use along with co-exposure to antidepressants, benzodiazepines, and 
gabapentin compared with opioids alone.31 However, given the main purpose of the study 
was to document the incidence of NAS, this was not felt to be a significant limitation. 
Moreover, despite a standardized statewide definition of NAS, there is a degree of 
subjectivity and individual variability in approaches when making NAS diagnosis and these 
differences in identification approaches are difficult to assess.32 Data collection for Project 
WATCH started in October 2016 and therefore cannot be retrospectively compared to 
traditional hospital billing data. Future research comparing Project WATCH and hospital 
billing data utilizing ICD codes is warranted. Moreover, non-punitive policies that enable 
early identification of NAS, improve access to comprehensive prenatal care and opioid 
replacement therapy, and increase funding for child welfare systems are also warranted. 
Additional resources are needed, especially to those sub-state regions with the highest rates 
of substance use and NAS. In addition, other states may benefit from a similar NAS 
surveillance system used by Project WATCH in WV.
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Prevalence of intra-uterine substance exposure (IUSE) and incidence of neonatal abstinence 
syndrome (NAS) in West Virginia from 1 October 2016 to 31 December 2017 for all births 
(N = 23,667) and for West Virginia residents only (N = 19,974)
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Project WATCH surveillance data on prevalence of intra-uterine substance exposure (IUSE) 
and neonatal abstinence syndrome (NAS) in West Virginia by SAMHSA sub-state regional 
classification system, N = 20,002
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Table 3.
One-month (January 2017) audit data for six hospitals in the state of WV comparing the project WATCH data 
with the hospital medical records and the ICD-10-CM codes (N = 789)
Data source Frequency Percent (95% CI)
Intrauterine substance exposure
 Hospital data 134 17.07 (14.36–19.60)
 Birth Score data 111 14.14 (11.64–16.49)
 ICD-10-CM code in chart—code P04. x 57 7.23 (5.42–9.03)
Neonatal abstinence syndrome
 Hospital data 79 10.1 (7.92–12.11)
 Birth Score data 67 8.55 (6.55–10.44)
 ICD-10-CM code in chart—code P96.1 43 5.46 (3.87–7.03)
Pediatr Res. Author manuscript; available in PMC 2020 April 01.
